1 May 2011AmericasRichard Korn and Stephanie Pilkington
Clinical trials and stratified medicine—maximising patent exclusivity
It is important to understand the likelihood of obtaining the required degree of exclusivity, whether through strong patent protection, data exclusivity or orphan designation. Richard Korn and Stephanie Pilkington look at how patent exclusivity can be enhanced as development progresses.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.
10 June 2026 Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit.
9 June 2026 A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.